Serum periostin is associated with fracture risk in postmenopausal women: A 7-year prospective analysis of the OFELY study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages 2533-2539

  Rousseau, J C ^a   Sornay Rendu, E ^a   Bertholon, C ^a   Chapurlat, R ^a   Garnero, P ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b Service de Rhumatologie et Pathologie Osseuse Hôpital E Herriot Université de Lyon ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; TRANSCRIPTION FACTOR RUNX2;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE DENSITY; BONE TURNOVER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; CELL ADHESION MOLECULES; COHORT STUDIES; FEMALE; FRANCE; HUMANS; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RISK FACTORS;

EID: 84902448166     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3893     Document Type: Article

References (37)

1. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact. 2004;4:50-63. (Pubitemid 38714795)
2. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813-1819. (Pubitemid 41361882)
3. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
4. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-1536. (Pubitemid 30484522)
5. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int. 2002;13:523-526. (Pubitemid 34790623)
6. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone. 2000;27:283-286. (Pubitemid 30458823)
7. Chopin F, Biver E, Funck-Brentano T, et al. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis. Joint Bone Spine. 2012;79:26-31.
8. Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res. 2002;17:826-833. (Pubitemid 34441899)
9. Coutu DL, Wu JH, Monette A, Rivard GE, Blostein MD, Galipeau J. Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J Biol Chem. 2008;283:17991-18001.
10. Merle B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos Int. 2012;23:1199-1212.
11. Kashima TG, Nishiyama T, Shimazu K, et al. Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum Pathol. 2009;40:226-237.
12. Zhu S, Barbe MF, Amin N, et al. Immunolocalization of Periostin-like factor and periostin during embryogenesis. J Histochem Cytochem. 2008;56:329-345. (Pubitemid 351429801)
13. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14:1239-1249. (Pubitemid 29314070)
14. Kruzynska-Frejtag A, Wang J, Maeda M, et al. Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction. Dev Dyn. 2004;229:857-868. (Pubitemid 38429114)
15. Kruzynska-Frejtag A, Machnicki M, Rogers R, Markwald RR, Conway SJ. Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation. Mech Dev. 2001;103:183-188. (Pubitemid 32457925)
16. Bonnet N, Standley KN, Bianchi EN, et al. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem. 2009;284:35939-35950.
17. Bonnet N, Conway SJ, Ferrari SL. Regulation of β catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci USA. 2012;109:15048-15053.
18. Xiao SM, Gao Y, Cheung CL, et al. Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk. Osteoporos Int. 2012;23:1877-1887.
19. Contie S, Voorzanger-Rousselot N, Litvin J, Clezardin P, Garnero P. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer. 2011;128:352-360.
20. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD. Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res. 1997;12:683-690. (Pubitemid 27155229)
21. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337-349. (Pubitemid 26076383)
22. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
23. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. (Pubitemid 23261108)
24. Szulc P, Garnero P, Marchand F, Duboeuf F, Delmas PD. Biochemical markers of bone formation reflect endosteal bone loss in elderly men-MINOS study. Bone. 2005;36:13-21. (Pubitemid 40128270)
25. Rios H, Koushik SV, Wang H, et al. Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol. 2005;25:11131-11144. (Pubitemid 41747153)
26. Yoshiba N, Yoshiba K, Hosoya A, et al. Association of TIMP-2 with extracellular matrix exposed to mechanical stress and its co-distribution with periostin during mouse mandible development. Cell Tissue Res. 2007;330:133-145. (Pubitemid 47438582)
27. Sasaki H, Yu CY, Dai M, et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003;77:245-252. (Pubitemid 36197639)
28. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for α(V)β(3) and α(V)β(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358-5364. (Pubitemid 35024613)
29. Shao R, Bao S, Bai X, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol. 2004;24:3992-4003. (Pubitemid 38496176)
30. Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol. 2005;25:77-83. (Pubitemid 40054257)
31. Bacchetta J, Boutroy S, Vilayphiou N, et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res. 2010;25:849-857.
32. Satirapoj B, Wang Y, Chamberlin MP, et al. Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant. 2012;27:2702-2711.
33. Guerrot D, Dussaule JC, Mael-Ainin M, et al. Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One. 2012;7:e31974.
34. Hakuno D, Kimura N, Yoshioka M, et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest. 2010;120:2292-2306.
35. Simon SP, Fodor D, Muntean L, Poanta L, Cristea P, Rednic S. Bone mineral density, vertebral fractures and body mass index in post-menopausal women with abdominal aortic calcification. Endocr Res. 2014;39(1):1-6.
36. Kim KJ, Kim KM, Park KH, et al. Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin. Calcif Tissue Int. 2012;91:370-378.
37. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004;89:4246-4253. (Pubitemid 39244420)